You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Moodys
Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Apabetalone

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Apabetalone?

Apabetalone is an investigational drug.

There have been 6 clinical trials for Apabetalone. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2015.

The most common disease conditions in clinical trials are Cardiovascular Diseases, Atherosclerosis, and Myocardial Ischemia. The leading clinical trial sponsors are Resverlogix Corp, PPD, and Medidata Solutions.

There are eighteen US patents protecting this investigational drug and two hundred and thirty-five international patents.

Recent Clinical Trials for Apabetalone
TitleSponsorPhase
Apabetalone for Pulmonary Arterial Hypertension: a Pilot StudySteeve ProvencherEarly Phase 1
Safety and Effect of Oral RVX000222 in Subjects With Fabry DiseaseResverlogix CorpPhase 1/Phase 2
A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With HemodialysisResverlogix CorpPhase 1/Phase 2

See all Apabetalone clinical trials

Clinical Trial Summary for Apabetalone

Top disease conditions for Apabetalone
Top clinical trial sponsors for Apabetalone

See all Apabetalone clinical trials

US Patents for Apabetalone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Apabetalone   Start Trial Pharmaceutical compositions for substituted quinazolinones Resverlogix Corp. (Calgary, Alberta, CA)   Start Trial
Apabetalone   Start Trial Compositions and therapeutic methods for the treatment of complement-associated diseases Resverlogix Corp. (Calgary, Alberta, CA)   Start Trial
Apabetalone   Start Trial Anti-inflammatory agents Resverlogix Corp. (Calgary, Alberta, CA)   Start Trial
Apabetalone   Start Trial 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, MI)   Start Trial
Apabetalone   Start Trial Nitric oxide-releasing prodrug molecule of substituted quinazolines ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (Linhai, CN) SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (Shanghai, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Apabetalone

Drugname Country Document Number Estimated Expiration Related US Patent
Apabetalone Australia 2012330885 2031-11-01   Start Trial
Apabetalone Canada 2851996 2031-11-01   Start Trial
Apabetalone China 103945848 2031-11-01   Start Trial
Apabetalone Denmark 2773354 2031-11-01   Start Trial
Apabetalone European Patent Office 2773354 2031-11-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Moodys
Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.